Wall Street analysts forecast that MiMedx Group, Inc. (NASDAQ:MDXG – Get Rating) will report ($0.10) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for MiMedx Group’s earnings. MiMedx Group reported earnings per share of ($0.09) in the same quarter last year, which indicates a negative year over year growth rate of 11.1%. The business is scheduled to issue its next quarterly earnings results on Monday, January 1st.
According to Zacks, analysts expect that MiMedx Group will report full year earnings of ($0.15) per share for the current financial year, with EPS estimates ranging from ($0.32) to ($0.03). For the next fiscal year, analysts expect that the company will report earnings of $0.05 per share, with EPS estimates ranging from ($0.22) to $0.31. Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that that provide coverage for MiMedx Group.
MiMedx Group (NASDAQ:MDXG – Get Rating) last released its quarterly earnings data on Monday, February 28th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.03) by $0.04. During the same period in the prior year, the company posted ($0.17) earnings per share.
NASDAQ:MDXG traded down $0.14 during trading hours on Wednesday, reaching $4.53. The stock had a trading volume of 450,258 shares, compared to its average volume of 551,554. The company has a debt-to-equity ratio of 586.91, a quick ratio of 3.24 and a current ratio of 3.51. MiMedx Group has a 52 week low of $4.12 and a 52 week high of $8.69. The company has a 50 day moving average price of $4.77 and a two-hundred day moving average price of $5.89. The stock has a market capitalization of $508.99 million, a PE ratio of -30.40 and a beta of 1.92.
In related news, General Counsel William Frank Iv Hulse sold 9,990 shares of the business’s stock in a transaction on Tuesday, March 8th. The stock was sold at an average price of $4.86, for a total transaction of $48,551.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Timothy R. Wright sold 61,000 shares of the business’s stock in a transaction on Wednesday, February 23rd. The shares were sold at an average price of $4.31, for a total value of $262,910.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 180,175 shares of company stock valued at $833,438. Company insiders own 19.80% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Teacher Retirement System of Texas boosted its holdings in MiMedx Group by 21.8% during the 4th quarter. Teacher Retirement System of Texas now owns 14,196 shares of the company’s stock valued at $86,000 after acquiring an additional 2,545 shares during the period. Lakeview Capital Partners LLC raised its position in MiMedx Group by 2.1% during the 4th quarter. Lakeview Capital Partners LLC now owns 128,073 shares of the company’s stock valued at $774,000 after purchasing an additional 2,683 shares in the last quarter. Metropolitan Life Insurance Co NY raised its position in MiMedx Group by 14.8% during the 4th quarter. Metropolitan Life Insurance Co NY now owns 23,239 shares of the company’s stock valued at $140,000 after purchasing an additional 3,001 shares in the last quarter. Principal Financial Group Inc. raised its position in MiMedx Group by 18.7% during the 3rd quarter. Principal Financial Group Inc. now owns 19,130 shares of the company’s stock valued at $116,000 after purchasing an additional 3,010 shares in the last quarter. Finally, Signaturefd LLC raised its position in MiMedx Group by 277.6% during the 3rd quarter. Signaturefd LLC now owns 4,761 shares of the company’s stock valued at $29,000 after purchasing an additional 3,500 shares in the last quarter. Institutional investors own 56.85% of the company’s stock.
About MiMedx Group (Get Rating)
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
- Get a free copy of the StockNews.com research report on MiMedx Group (MDXG)
- 3 Undervalued Stocks The Insiders Are Buying
- The Market For Gamestop Is Near A Turning Point
- PayPal Stock is Still Ready for Bargain Hunting
- It’s Personal: 3 Personal Care Stocks to Own in Volatile Markets
- Conagra Stock Has More Room to Grow
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.